-5%
Linax-E Tablet is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Linax-E combines Linagliptin and Empagliflozin, two antidiabetic agents with complementary mechanisms of action.
Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases levels of active incretin hormones such as GLP-1 and GIP. These hormones enhance glucose-dependent insulin secretion and reduce glucagon release, helping to improve blood glucose control.
Empagliflozin is a sodium-glucose co-transporter-2 (SGLT2) inhibitor. It lowers blood glucose by reducing renal glucose reabsorption, thereby increasing urinary glucose excretion and lowering plasma glucose levels.